BCL2 and acute myeloid leukemia: Other preclinical studies demonstrate the efficacy of CB-839 in AML cells, especially those harboring specific genetic defects such as isocitrate dehydrogenase (IDH)-mutated AML cells [91] or in combination with other drugs, such as the BH3 mimetic ABT-199, which specifically inhibits BCL-2 [92].